Our mission
Our progress
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Mereo BioPharma today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm GMT / 07:55am ET.
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
28 October 2022
Mereo BioPharma Group plc today announced it has entered into a cooperation agreement (the “Agreement”) with Rubric Capital Management LP (“Rubric”), its largest shareholder. Pursuant to the Agreement, four new directors – Dr. Annalisa Jenkins, Dr. Daniel Shames, Mr. Marc Yoskowitz and Mr. Justin Roberts – will be appointed to the Company’s Board of Directors as soon as practicable. Concurrent with these appointments taking effect, directors Dr. Peter Fellner, Dr. Brian Schwartz, Dr. Abdul Mullick and Ms. Anne Hyland will resign from the Board.
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
Mereo BioPharma today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD). The update will include commentary from and Q&A with leading pulmonary experts, further to the receipt of Fast Track Designation for alvelestat from the FDA announced on October 17, 2022.
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
21 October 2022
Driven by a true understanding of the critical nature of our mission, we harness the power of science and meaningful relationships to create new possibilities for patients who need them.
